Commentary: The Impetus to Explore Alternative Courses of Treatment for Overactive Bladder

Citation: Orlin Yaacov. Commentary: The Impetus to Explore Alternative Courses of Treatment for Overactive Bladder. J Clin Med Current Res. (2022);2(2): 1-2 1. Background Twenty-five million Americans and 200 million people worldwide suffer from incontinence and overactive bladder syndrome (OAB), costing the US economy upward of $80 billion annually [1]. According to the CDC, the average patient suffers for over six years before consulting their doctor about their bladder issues, 64% of patients that discuss their symptoms with a physician reach the conclusion that OAB is an illness that they are just going to have to live with [2]. 92% of all OAB patients have discontinued treatment due to lack of efficacy or adverse effects within two years [2]. Recently approved drug classes, including beta-3 adrenergic agonists and advances in neuromodulation along with the acceptance of telemedicine and big-data-driven care, lead this author to believe that it is time to rethink the paradigm of OAB care.